Sign In
Buy ZURA
$4.31
+0.0750 (+1.77%)
At Close: Jun 23, 2026
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
06:30am, Tuesday, 25'th Mar 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-path
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
06:30am, Monday, 24'th Feb 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for au
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
10:36am, Friday, 24'th Jan 2025
Zura Bio Limited (ZURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
06:30am, Monday, 23'rd Dec 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults.
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
06:30am, Monday, 25'th Nov 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for au
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for au
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
06:30am, Thursday, 07'th Nov 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for au
Zura Bio to Participate in Two Upcoming Investor Conferences in November
06:30am, Wednesday, 30'th Oct 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for au
CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology
06:00am, Tuesday, 03'rd Sep 2024
SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics t
3 Undervalued Biotech Stocks With Breakout Potential
06:00am, Friday, 19'th Jul 2024
Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
06:08am, Friday, 12'th Jul 2024
There's always a strong case for undervalued biotech stocks. For one, the industry is only expected to grow.
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
06:00am, Friday, 14'th Jun 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology
06:00am, Thursday, 06'th Jun 2024
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Forms Scientific Advisory Board with Prominent Specialists.
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and
Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know
10:56am, Friday, 31'st May 2024
The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
